Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...

There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things. Researchers at the University of Basel have now been able to use artificial ...

The drug inhibits progression of epidermolysis bullosa in skin. Recessive dystrophic pidermolysis bullosa (RDEB) leads to excessive deposition of fibrosis (COL I) in the skin in response to skin ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Overall Count and Share for 'European Reference Network for Rare and Undiagnosed Skin Disorders (ERN-Skin)' based on the 12-month time frame mentioned above. Note: Articles may be assigned to more ...

LAS VEGAS (KVVU/CNN Newsource/WKRC) - A 7-year-old boy from Nevada is finally able to sleep with his eyes closed after undergoing a life-changing eyelid surgery. Carter Bresee, who has two rare skin ...

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line ...

The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...